Chinese Japanese Germany Korea


Product description Approved indications in Europe, the United States and other countries Precautions Uses
Imatinib structure
Chemical Name:
IMA-3;Veenat;matinib;ST-1571;IMATINIB;CGP057148B;AKOS 91378;IMatinib-D4;IMATINIB-D3;IMATINIB 99+%
Molecular Formula:
Formula Weight:
MOL File:

Imatinib Properties

Melting point:
208-210°C (dec.)
storage temp. 
pKa1 8.07; pKa2 3.73; pKa3 2.56; pKa4 1.52(at 25℃)
CAS DataBase Reference
152459-95-5(CAS DataBase Reference)


Safety Statements  24/25
RTECS  CV5585673
HS Code  29339900

Imatinib price More Price(2)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
TCI Chemical I0906 Imatinib >98.0%(HPLC) 152459-95-5 100mg $49 2018-11-22 Buy
TCI Chemical I0906 Imatinib >98.0%(HPLC) 152459-95-5 1g $147 2018-11-22 Buy

Imatinib Chemical Properties,Uses,Production

Product description

Imatinib is a kind of oral drugs used for the treatment of the chronic myelogenous leukemia (abbreviated CML) of positive symptoms of Philadelphia chromosome (Ber-Abl). It is suitable for being applied to adult patients in acute transformation phase, accelerated phase, and chronic phase with treatment failure with interferon. CML is a kind of hematopoietic stem cell disease caused by the DNA abnormalities in the bone marrow stem cells. DNA abnormalities will produce abnormal proteins and interfere with the normal generation process of the white blood cells in the bone marrow, resulting in the sharp increase in the number of white blood cells. CML is divided into three phases including chronic phase, accelerated phase and crisis phase with the average survival period of the patients in crisis phase being only 2-3 months.
Imatinib is also effective in treating the gastrointestinal stromal tumor with the efficiency being about 50%.

Approved indications in Europe, the United States and other countries

Novartis's imatinib (imatinib, Glivec) had been approved in Switzerland for being used as first-line drug for the treatment of early-stage adult chronic myelogenous leukemia and can also be applied to patients with various types of chronic granulocytic leukemia. Switzerland is the first countries which had approved to additionally include the above two indications of this drug.
On July 28, 2006, the European Agency for the Evaluation of Medicinal Products (EMEA) had recommended the imatinib (Gleevec) of the Novartis Company for the treatment of two new indications-dermatofibrosarcoma protuberans (DFSP) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL). These final approvals of these two indications still need to wait the decision of the European Food and Drug Administration.
In addition, Novartis has announced that the application of imatinib in treating hypereosinophilic syndrome and systemic mastocytosis is still in the approval process of FDA and EMEA.
The drug has currently been approved in Europe, the United States and other countries for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph + CML) and gastrointestinal stromal tumors.
The above information is edited by the Chemicalbook of Dai Xiongfeng.


When combined with Ketoconazole, itraconazole, erythromycin, clarithromycin, the Cmax of this drug can (the maximum plasma concentration after the first drug administration) be increased by an average of 26% with the AUC being increased by 40%.
The inducers of the metabolizing enzyme of hepatic drugs such as dexamethasone, phenytoin, carbamazepine, rifampicin and barbiturates can significantly reduce blood concentration of the drug.
When the CYP3A4 metabolized substrates such as simvastatin, cyclosporine, pimozide, etc. were used in combined with imatinib, the plasma concentration of those drugs can be increased due to its competing with the drug enzyme.


Imatinib can be used for the treatment of the chronic myelogenous leukemia (abbreviated CML) of positive symptoms of Philadelphia chromosome (Ber-Abl). It is suitable for being applied to adult patients in acute transformation phase, accelerated phase, and chronic phase with treatment failure with interferon.

Chemical Properties

Orange Solid


Imatinib Mesylate is orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively. Imatinib also known as Gleevec, Glivec, CGP-57148B, STI-571 & Imatinib




atypical antipsychotic


Imatinib impurity.


Bcr-Abl inhibitor imatinib (Gleevec(R), Novartis) was approved in 2001 by the FDA. Although fasudil was approved in 1995, imatinib is widely perceived as the first approved SMKI mainly owing to the fact that fasudil's kinase inhibitory mechanism was unknown at the time of approval, and efforts to gain approval of fasudil have been unsuccessful in the United States and Europe.
The field of kinase inhibitor development has evolved rapidly since the approval of imatinib. Some of the key discoveries and events include (i) the discovery of MAPK/ERK inhibitors, for example, CI-1040 (PD184352), as the first series of type III inhibitors in 2003; (ii) the approval of first dual tyrosine kinase and serine/threonine kinase inhibitor sorafenib in 2005; (iii) the description of the first series of allosteric type IVkinase inhibitor, that is,GNF-2 and analogues that inhibit Bcr–Abl through an allosteric non-ATP-competitivemode, by Gray and coworkers in 2006; (iv) the approval of the first type III inhibitor trametinib in 2013; (v) the approval of the first covalent kinase inhibitors, afatinib and ibrutinib, in 2013; and (vi) the approval of the first lipid kinase inhibitor, that is, the PI3K inhibitor idelalisib, in 2014.
By December 2016, kinase inhibitor drug discovery can leverage the structures of over 200 human kinases and 5000 kinases of all types, over 1 million publications, clinical data from more than 200 molecules currently in phase I–III trials, and post-marketing results from the approved 38 drugs.

Imatinib Preparation Products And Raw materials

Raw materials

Preparation Products

Imatinib Suppliers

Global( 309)Suppliers
Supplier Tel Fax Email Country ProdList Advantage
Capot Chemical Co.,Ltd.
+86 (0)571-855 867 18
+86 (0)571-858 647 95 China 19947 60
Henan DaKen Chemical CO.,LTD.
+86-371-55531817 CHINA 22064 58
Chengdu Henghui Pharm Tec Co. Ltd.
13540674322 15828370308,QQ:2879822141
028-89481236 CHINA 121 55
Beijing Cooperate Pharmaceutical Co.,Ltd.
+86-10-60279497 +86(0)15646567669
+86-10-60279497 CHINA 1530 55
Henan Tianfu Chemical Co.,Ltd.
0371-55170693 CHINA 20743 55
Mainchem Co., Ltd.
+86-0592-6210733 CHINA 32606 55
020-81716319 CHINA 2543 55
Shanghai Yingrui Biopharma Co., Ltd.
+86-21-34979012 CHINA 663 60
Hubei XinRunde Chemical Co., Ltd.
+8615102730682; +8618874586545
02783214688 CHINA 548 55
+86 21 5161 9050/ 5187 7795
+86 21 5161 9052/ 5187 7796 CHINA 24212 60

View Lastest Price from Imatinib manufacturers

Image Release date Product Price Min. Order Purity Supply Ability Manufacturer
2018-08-20 Imatinib
US $1.00 / KG 1G 98% 100KG career henan chemical co
2018-07-23 Imatinib
US $2500.00 / KG 2KG 99% 20tons career henan chemical co
2018-03-14 Imatinib 152459-95-5
US $1.00 / KG 1G 99% 1MT Hubei XinRunde Chemical Co., Ltd.

152459-95-5(Imatinib)Related Search:

  • matinib
  • Imatinib (4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide
  • Imatinib free base
  • Veenat
  • IMatinib(STI571)
  • Imantinib base
  • 4-(4-Methyl-piperazin-1-ylMethyl)-N-[4-Methyl-3-(4-pyridin-3-yl-pyriMidin-2-ylaM
  • IMatinib-D4
  • IMatinib (Gleevec)
  • 4-[(4-Methylpiperazin-1-yl)Methyl]-N-[4-Methyl-3-
  • 1-Methyl-4-(4-((4-Methyl-3-((4-(pyridin-3-yl)pyriMidin-2-yl)aMino)phenyl)carbaMoyl)benzyl)piperazine 1,4-dioxide
  • IMatinib SynonyMs 4-[(4-Methylpiperazin-1-yl)Methyl]-N-[4-Methyl-3-[(4-pyridin-3-ylpyriMidin-2-yl)aMino]phenyl]benzaMide
  • 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide
  • CGP057148B
  • ST-1571
  • IMA-3
  • AKOS 91378
  • IMATINIB 99+%
  • Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
  • Imatinib Mesilate
  • 4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide methanesulfonate
  • Imatinib,Gleevec,Glivec,STI-571
  • 4,4'-(piperazine-1,4-diylbis(Methylene))bis(N-(4-Methyl-3-((4-(pyridin-3-yl)pyriMidin-2-yl)aMino)phenyl)benzaMide)
  • 4-Methyl-1-(4-((4-Methyl-3-((4-(pyridin-3-yl)pyriMidin-2-yl)aMino)phenyl)carbaMoyl)benzyl)piperazine 1-oxide
  • CGP-57148B, STI-571
  • -
  • Imatinib 152459-95-5
  • 152459-95-5
  • 152459-95-9
  • C29H31N7O
  • Inhibitors
  • Molecular Targeted Antineoplastic
  • 1144803-18-1
  • Pharmaceutical intermediate
  • Imatinib
  • Aromatics
  • Heterocycles
  • Impurities
  • Intermediates & Fine Chemicals
  • Pharmaceuticals
  • API
  • Antineoplastic
  • Anti-cancer & immunity
Copyright 2017 © ChemicalBook. All rights reserved